|
Group
|
Weeks post the first vaccination
|
|---|
|
0
|
2
|
4
|
6
|
8
|
|---|
|
NA
|
HI
|
NA
|
HI
|
NA
|
HI
|
NA
|
HI
|
NA
|
HI
|
|---|
|
rPRV-VP2-IL6
|
-b
|
0
|
1:2
|
2.5 ± 0.2* c
|
1:8
|
4.1 ± 0.3*
|
1:32
|
5.3 ± 0.2*
|
1:128
|
6.9 ± 0.3*
|
|
rPRV-VP2-EGFP
|
–
|
0
|
1:2
|
2.0 ± 0.2*
|
1:8
|
3.9 ± 0.2*
|
1:32
|
5.0 ± 0.3*
|
1:64
|
6.5 ± 0.2*
|
|
PPV vaccine
|
–
|
0
|
–
|
4.0 ± 0.3*
|
–
|
6.3 ± 0.3*
|
–
|
5.6 ± 0.2*
|
–
|
7.6 ± 0.3*
|
|
PRV HB98
|
–
|
0
|
1:2
|
0
|
1:8
|
0
|
1:32
|
0
|
1:128
|
0
|
|
DMEM
|
–
|
0
|
–
|
0
|
–
|
0
|
–
|
0
|
–
|
0
|
- aValues are expressed as mean HI antibody titer ± standard error
- bNA titers <2
- cStatistically significant differences (P < 0.05) are indicated by*(compared with compared with PRV HB98 or DMEM)
